Advanced Medical Optics (EYE)

Cataract/implant sales during the first quarter were $120.4 million, up 3.2 percent, net of a 5.1 percent decrease related to foreign currency. The growth reflected increased sales of technologically advanced products, partially offset by declining sales of discontinued, non-strategic products. Below are highlights of cataract/implant categories for the first quarter of 2006. Growth rates reflect comparisons to the same period in 2005 and include the impacts of foreign currency.

•                  Intraocular lens (IOL) sales rose 8.9 percent to $66.3 million, due primarily to increased sales of Tecnis® and other premium IOLs, which were partially offset by the accelerated phase-out of older-generation silicone and PMMA (polymethyl methacrylate) IOLs. AMO’s refractive IOLs – Tecnis® Multifocal, ReZoom^TM and Verisyse^TM – contributed $10.3 million to IOL sales in the quarter. This compared to nearly $9 million in the fourth quarter of 2005 and about $4 million in the year-ago quarter. The company now expects to generate between $50 million and $60 million in 2006 refractive implant sales, representing a $5 million increase over its prior forecast.

•                  Phacoemulsification sales rose 13.8 percent to $21.4 million. Strong sales of AMO’s proprietary Sovereignâ systems with WhiteStarâ technology, as well as the surgical packs and accessories that support these systems, led this growth.

•                  Viscoelastics sales declined 10.2 percent to $28.9 million, as Healon® product performance was masked by declining sales of discontinued viscoelastics, reimbursement pressures in certain international markets and unfavorable foreign currency translations.

Cataract/Implant: